{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+Placebo+%280.5mL+injection%29", "query": { "intervention": "Saline Placebo (0.5mL injection)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 28, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+Placebo+%280.5mL+injection%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-27T08:51:37.735Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02515175", "title": "Evaluating New Formulation of Therapeutic HSV-2 Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Genital Herpes Simplex Type 2" ], "interventions": [ { "name": "Matrix-M2", "type": "BIOLOGICAL" }, { "name": "GEN-003", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Genocea Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 131, "start_date": "2015-11", "completion_date": "2017-05-25", "has_results": false, "last_update_posted_date": "2018-05-22", "last_synced_at": "2026-09-27T08:51:37.735Z", "location_count": 8, "location_summary": "Birmingham, Alabama • San Diego, California • San Francisco, California + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02515175" }, { "nct_id": "NCT00941889", "title": "The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Positive", "Anal Condylomata", "Anal Warts", "HIV Infections" ], "interventions": [ { "name": "Saline", "type": "DRUG" }, { "name": "Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2007-07", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2016-07-25", "last_synced_at": "2026-09-27T08:51:37.735Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00941889" }, { "nct_id": "NCT07771725", "title": "Impact of Sweeteners on the Addictive Threshold of Nicotine", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Smoking ( Cigarette)" ], "interventions": [ { "name": "Nicotine 0.05 mg/pulse and 0.1 mg/pulse", "type": "DRUG" }, { "name": "Saline Placebo (0.5mL injection)", "type": "DRUG" }, { "name": "sucralose", "type": "DIETARY_SUPPLEMENT" }, { "name": "Sugar syrup (Placebo)", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "59 Years", "sex": "ALL", "summary": "21 Years to 59 Years" }, "enrollment_count": 36, "start_date": "2026-09-01", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-09-27T08:51:37.735Z", "location_count": 1, "location_summary": "West Haven, Connecticut", "locations": [ { "city": "West Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT07771725" }, { "nct_id": "NCT03048929", "title": "Inflammation and Threat Sensitivity in PTSD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Posttraumatic Stress Disorder" ], "interventions": [ { "name": "Typhoid Vi Polysaccharide Vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "30 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "30 Years to 60 Years" }, "enrollment_count": 30, "start_date": "2019-04-01", "completion_date": "2021-03-31", "has_results": false, "last_update_posted_date": "2021-05-13", "last_synced_at": "2026-09-27T08:51:37.735Z", "location_count": 2, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03048929" }, { "nct_id": "NCT02247726", "title": "RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Respiratory Syncytial Virus Infections" ], "interventions": [ { "name": "Saline Placebo (0.5mL injection)", "type": "DRUG" }, { "name": "RSV F vaccine (0.5mL injection)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novavax", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "18 Years to 40 Years · Female only" }, "enrollment_count": 50, "start_date": "2014-09", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2022-05-27", "last_synced_at": "2026-09-27T08:51:37.735Z", "location_count": 7, "location_summary": "Nampa, Idaho • Hutchinson, Kansas • Kansas City, Kansas + 4 more", "locations": [ { "city": "Nampa", "state": "Idaho" }, { "city": "Hutchinson", "state": "Kansas" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Norfolk", "state": "Nebraska" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02247726" }, { "nct_id": "NCT01475786", "title": "Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Painful Diabetic Neuropathies" ], "interventions": [ { "name": "Low Dose: 16 mg Engensis (VM202)", "type": "BIOLOGICAL" }, { "name": "High Dose: 32 mg Engensis (VM202)", "type": "BIOLOGICAL" }, { "name": "Control- Placebo (normal saline)", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Helixmith Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 104, "start_date": "2012-08", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2025-10-06", "last_synced_at": "2026-09-27T08:51:37.735Z", "location_count": 13, "location_summary": "Walnut Creek, California • Orlando, Florida • Palm Beach Gardens, Florida + 9 more", "locations": [ { "city": "Walnut Creek", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Palm Beach Gardens", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01475786" }, { "nct_id": "NCT06810934", "title": "A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "COVID-19", "SARS-CoV-2 Infection" ], "interventions": [ { "name": "CoTend-BXBB (SARS2-30404)", "type": "BIOLOGICAL" }, { "name": "CoTend-s3BXBB (SARS2-17032)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Kara Chew", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "40 Years to 64 Years" }, "enrollment_count": 80, "start_date": "2025-10-21", "completion_date": "2029-10", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-09-27T08:51:37.735Z", "location_count": 2, "location_summary": "Los Angeles, California • San Francisco, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06810934" }, { "nct_id": "NCT01147068", "title": "Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "0.5mL Intramuscular Injection", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Protein Sciences Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 392, "start_date": "2010-06", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2012-11-26", "last_synced_at": "2026-09-27T08:51:37.735Z", "location_count": 4, "location_summary": "Overland Park, Kansas • Omaha, Nebraska • Rochester, New York + 1 more", "locations": [ { "city": "Overland Park", "state": "Kansas" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Rochester", "state": "New York" }, { "city": "Fort Worth", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01147068" }, { "nct_id": "NCT02788045", "title": "Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Ad26.Mos.HIV", "type": "BIOLOGICAL" }, { "name": "Ad26.Mos4.HIV", "type": "BIOLOGICAL" }, { "name": "Clade C gp140", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Janssen Vaccines & Prevention B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 201, "start_date": "2016-07-08", "completion_date": "2022-04-25", "has_results": true, "last_update_posted_date": "2025-05-25", "last_synced_at": "2026-09-27T08:51:37.735Z", "location_count": 9, "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Silver Spring", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02788045" }, { "nct_id": "NCT01064440", "title": "Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Critical Limb Ischemia" ], "interventions": [ { "name": "Low Dose VM202", "type": "BIOLOGICAL" }, { "name": "High Dose VM202", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Helixmith Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 52, "start_date": "2010-07-09", "completion_date": "2023-11-17", "has_results": true, "last_update_posted_date": "2025-10-06", "last_synced_at": "2026-09-27T08:51:37.735Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Orange, California • Chicago, Illinois + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01064440" } ] }